DANUBE: A Phase 3 randomised study of first-line durvalumab (MEDI4736) ± tremelimumab vs standard of care (SoC) chemotherapy (CT) in patients (pts) with Stage IV urothelial carcinoma (UC)

被引：0
|
作者：
Park, S. H. [1 ]
Castellano, D. [2 ]
Petrylak, D. P. [3 ]
Galsky, M. D. [4 ]
van der Heijden, M. S. [5 ]
Loriot, Y. [6 ]
Ogawa, O. [7 ]
Su, W-P. [8 ]
Huang, W. [9 ]
Levin, W. [9 ]
Ferro, S. [9 ]
Ben, Y. [9 ]
Bellmunt, J. [10 ]
Powles, T. [11 ]
机构：
[1] Samsung Med Ctr, Dept Med, Seoul, South Korea
[2] Hosp Univ 12 Octubre, Dept Med Oncol, Madrid, Spain
[3] Yale Univ, Dept Med, New Haven, CT 06520 USA
[4] Icahn Sch Med Mt Sinai, Dept Med, New York, NY 10029 USA
[5] Netherlands Canc Inst, Dept Med Oncol, Amsterdam, Netherlands
[6] Inst Gustave Roussy, Dept Canc Med, Villejuif, France
[7] Kyoto Univ, Dept Urol, Kyoto, Japan
[8] Natl Cheng Kung Univ Hosp, Dept Internal Med, Tainan, Taiwan
[9] AstraZeneca, Global Med Dev, Gaithersburg, MD USA
[10] Harvard Med Sch, Dana Farber Canc Inst, Bladder Canc Ctr, Boston, MA USA
[11] Queen Mary Univ London, Barts Canc Inst, Expt Canc Med Ctr, London, England
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
285TiP
引用
收藏
页数：2
相关论文
共 50 条
  • [31] A phase III study of MEDI4736 (M), an anti-PD-L1 antibody, in monotherapy or in combination with Tremelimumab (T), versus standard of care (SOC) in patients (pts) with advanced non-small cell lung cancer (NSCLC) who have received at least two prior systemic treatment regimens (ARCTIC).
    Planchard, David
    Shtivelband, Mikhail
    Shi, Kelvin
    Ibrahim, Ramy
    Ballas, Marc
    Soria, Jean-Charles
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [32] Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical Trial (vol 6, pg 661, 2020)
    Rizvi, N. A.
    Cho, B. C.
    Reinmuth, N.
    JAMA ONCOLOGY, 2020, 6 (11) : 1815 - 1815
  • [33] FIGHT-205: Phase II study of first-line pemigatinib (PEMI) plus pembrolizumab (PEMBRO) versus PEMI alone versus standard of care (SOC) for cisplatin (CIS)-Ineligible urothelial carcinoma (UC) with FGFR3 mutation or rearrangement
    Galsky, Matt D.
    Powles, Thomas
    Dreicer, Robert
    Kitamura, Hiroshi
    Asatiani, Ekatherine
    Howe, Jason
    Zhen, Huiling
    Oliveira, Natalia
    Necchi, Andrea
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [34] A Phase 3, randomized study of first-line durvalumab (D) plus /- tremelimumab (T) plus platinum-based chemotherapy (CT) vs CT alone in extensive disease small-cell lung cancer (ED-SCLC): CASPIAN
    Alt, J.
    Bischoff, H. G.
    Laack, H-E
    Leistner, R. D.
    Panse, J.
    Reinmuth, N.
    Schulz, C.
    Grohe, C.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 103 - 103
  • [35] A phase 3 study of first-line durvalumab vs platinum-based chemotherapy in patients with advanced NSCLC and high PD-L1 expression: PEARL
    Wu, Y-L.
    Lu, S.
    Clarke, S.
    Lactionov, K.
    Li, P.
    Kirkby, M.
    Xie, Y.
    Stockman, P.
    ANNALS OF ONCOLOGY, 2017, 28
  • [36] A randomized, multicenter, phase 3 study of nivolumab vs sorafenib as first-line treatment in patients (pts) with advanced hepatocellular carcinoma (HCC): CheckMate-459.
    Sangro, Bruno
    Park, Joong-Won
    Dela Cruz, Christine Marie
    Anderson, Jeffrey
    Lang, Lixin
    Neely, Jaclyn
    Shaw, James W.
    Cheng, Ann-Lii
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [37] A phase 3, open-label, randomized study of nivolumab plus ipilimumab or standard of care (SoC) vs SoC alone in patients with previously untreated unresectable or metastatic urothelial carcinoma (CheckMate 901)
    Waller, C. F.
    Galsky, M. D.
    Powles, T.
    van der Heijden, M. S.
    Li, S.
    Hennicken, D.
    Sonpavde, G.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 324 - 325
  • [38] MYSTIC - A Phase III, randomized, open-label study of Durvalumab (MED14736) in combination with Tremelimumab or Durvalumab alone versus platinum-based chemotherapy in first-line treatment of patients with advanced stage IV non small cell lung cancer (aNSCLC): A German update
    von Pawel, J.
    Fischer, J.
    Alt, J.
    Rittmeyer, A.
    Wehler, T.
    Laack, E.
    Griesinger, F.
    Schneider, C. P.
    Panse, J.
    Dieing, A.
    Rawluk, J.
    Serke, M.
    Kropf-Sanchen, C.
    Lerchenmueller, C.
    Bohnet, S.
    Bischoff, H.
    Nusch, A.
    de Wit, M.
    Rupprecht, M.
    Alt, A.
    McIntosh, S.
    Rizvi, N. A.
    Seggewiss-Bernhardt, R.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 87 - 87
  • [39] A phase 3, open-label, randomized study of nivolumab plus ipilimumab or standard of care (SOC) versus SOC alone in patients (pts) with previously untreated unresectable or metastatic urothelial carcinoma (mUC; CheckMate 901).
    Galsky, Matt D.
    Powles, Thomas
    Li, Shengting
    Hennicken, Delphine
    Sonpavde, Guru
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [40] Nomogram-based prediction of overall survival (OS) of patients (pts) with metastatic urothelial carcinoma (UC) receiving first-line platinum-based chemotherapy: retrospective international study of invasive/advanced cancer of the urothelium (RISC)
    Necchi, A.
    Sonpavde, G.
    Lo Vullo, S.
    Bamias, A.
    Crabb, S. J.
    Harshman, L.
    Bellmunt, J.
    De Giorgi, U.
    Sternberg, C.
    Ladoire, S.
    Wong, Y-N.
    Yu, E. Y.
    Chowdhury, S.
    Niegisch, G.
    Srinivas, S.
    Vaishampayan, U.
    Pal, S. K.
    Rosenberg, J.
    Mariani, L.
    Galsky, M. D.
    ANNALS OF ONCOLOGY, 2016, 27
12345